prt3645

Sarcoma

Prelude TherapeuticsPhase 1Active

CC

42/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 73/ 100

Competitive context

109 Active assets in the Sarcoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BB
Cyclophosphamide Essen Biotech	Phase 2	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
Inno-206 City of Hope Medical Center	Phase 3	BB
Carboplatin OHSU Knight Cancer Institute	Phase 2	BB

View all 50 →

Same molecule, other indications

prt3645 is also rated in:

malignant mesotheliomaDormant

CC

Indicative ·

47 / 100

non-small cell lung carcinomaDormant

CC

Indicative ·

47 / 100

glioblastomaDormant

CC

Indicative ·

40 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.